Sichuan Kelun-Biotech Biopharmaceutical valuation

6990 · HKEX · HKD

Compare Sichuan Kelun-Biotech Biopharmaceutical
$398.40Change from previous close: −5.59%Absolute change: −$23.60

Close · November 20, 2026

Valuation

The P/E ratio is 553.3. The average price target of 20 analysts is $617.60.

Data as of November 22, 2026

Sichuan Kelun-Biotech Biopharmaceutical compared with similar companies

Sichuan Kelun-Biotech Biopharmaceutical's Forward P/E: 121.7, +284% against the median of a group of 11 similar companies (31.7).

Sichuan Kelun-Biotech Biopharmaceutical's metrics compared with similar companies
MetricSichuan Kelun-Biotech BiopharmaceuticalMedian25th–75th percentileBand
Forward P/E121.731.722.2 – 41.7High
Price/book14.84.162.56 – 7.85High
Price/sales45.79.885.78 – 31.6High
Gross margin74.6%74.6%56.9% – 79.1%Middle
Operating margin-0.2%21.1%10.7% – 32.0%Low
Net margin7.2%11.1%7.2% – 26.8%Middle
ROE2.9%10.4%5.0% – 19.8%Low
Debt/equity0.020.110.05 – 0.38Low

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$95.23B
Enterprise value
$88.21B
P/E (trailing 12 months)
553.3
EV/EBITDA
1,490.7
EV/revenue
42.3

Profitability and growth

ROA
-0.0%
ROIC
-0.0%
Revenue growth (year over year)
2.9%
Earnings growth (year over year)
-361.1%

Financial health

Total cash
$4.78B
Total debt
$81.35M
Current ratio
6.34
Quick ratio
5.98
Altman Z-Score
55.8
Piotroski F-Score
5.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
$617.60
Median price target
$625.00
High price target
$765.30
Low price target
$520.00
Analysts with a price target
20
Consensus
Strong buy
Forward EPS
$3.27
EPS estimate, current year
$0.81

Shares and trading

Beta
0.10
Average volume
694.16K
Shares outstanding
176.82M
Float
97.58M
Institutional ownership
28.0%
Insider ownership
58.9%